白蛋白紫杉醇联合卡铂一线治疗晚期肺鳞癌的疗效分析  

Efficacy of Albumin-Bound Paclitaxel and Carboplatin as a First-Line Treatment for Advanced Lung Squamous Cell Carcinoma

作　　者：陈秀 万国峰 孙丽[1] 李鹏 盛敏[2] 赵绍民[1] CHEN Xiu;WAN Guofeng;SUN Li;LI Peng;SHENG Min;ZHAO Shaomin(Department of Pulmonary and Critical Care Medicine,Zaozhuang Municipal Hospital,Zaozhuang Shandong 277100,China;Department of Health,Zaozhuang Municipal Hospital,Zaozhuang Shandong 277100,China)

机构地区：[1]枣庄市立医院呼吸与危重症医学科,山东枣庄277100 [2]枣庄市立医院保健科,山东枣庄277100

出　　处：《中国卫生标准管理》2024年第17期144-149,共6页China Health Standard Management

摘　　要：目的观察白蛋白紫杉醇和卡铂联用作为一线治疗方案对晚期肺鳞状细胞癌患者的临床效果及不良反应。方法选取2020年12月—2022年12月于枣庄市立医院呼吸与危重症医学科接受治疗的86例晚期肺鳞状细胞癌(ⅢB/Ⅳ期)患者作为研究对象,根据随机数表法分为NC组(给予白蛋白结合型紫杉醇联合卡铂治疗方案,n=40)与GC组(给予吉西他滨联合卡铂的治疗方案,n=46)。比较2组的临床疗效及不良反应。结果2组的客观缓解率和疾病控制率比较,NC组分别为40%(16/40)和72.5%(29/40)。GC组分别为26%(12/46)和65.2%(30/46)。2组近期疗效对比表明NC组较GC组客观缓解率提高14%,但差异无统计学意义(P>0.05)。2组患者无进展生存期分别为5.10个月和4.60个月,差异无统计学意义(P>0.05)。2组均出现骨髓抑制、恶心/呕吐、腹泻、周围神经毒性及肌痛/关节痛等症状,其中血小板减少发生率NC组较GC组低,周围神经毒性发生率NC组较GC组高,差异有统计学意义(P<0.05)。2组其他不良反应发生率比较,差异无统计学意义(P>0.05)。结论将白蛋白紫杉醇与卡铂联合应用作为治疗晚期肺鳞癌患者的首选方案,在安全和疗效上都得到了正面评价,由此带来的不良反应在可控范围之内,有必要扩充样本规模进行更深入的探讨和验证。Objective To observe the clinical effects and adverse effects of albumin-bound paclitaxel and carboplatin as a first-line treatment for advanced lung squamous cell carcinoma.Methods A total of 86 patients with advanced lung squamous cell carcinoma(stageⅢB/Ⅳ)treated in the department of respiratory and critical care medicine,Zaozhuang Municipal Hospital from December 2020 to December 2022 were selected as the study subjects.Patients were divided into experimental and control groups according to the random number table method.The experimental group received albumin-combined paclitaxel with carboplatin(NC experimental group,sample number of 40 patients),and the control group received gemcitabine and carboplatin(GC control group,46 samples).To compare the clinical efficacy and adverse effects.Results The comparison between the objective response rate and the disease control rate.The patients who were treated with nab-Paclitaxel plus carboplatin(group NC)had an objective response rate of 40%(16/40).The disease control rates was 72.5%(29/40).Meanwhile,the patients who were treated with gemcitabine plus carboplatin(group GC)had an objective response rate of 26%(12/46);.The disease control rates(DCR)was 65.2%(30/46).Our results suggested that ORR improved 14%in group NC,compared to that in group GC.However,there was no significant difference in short-term efficacy between two groups(P>0.05).The median progression-free survival(PFS)was 5.10 months in group NC and 4.60 months in group GC.Progression-free survival in two groups showed no significant difference(P>0.05).All the two groups showed myelosuppression,nausea/vomiting,diarrhea,toxicity of peripheral nerve,myalgia/arthralgia,etc.Among them,the incidence of thrombocytopenia in NC group was lower than that of GC group,and the incidence of peripheral neurotoxicity in NC group was higher than that of GC group,with statistically significant differences(P<0.05).Comparison of other adverse effects,no significant difference(P>0.05).Conclusion Administering a combination

关 键 词：白蛋白结合型紫杉醇 卡铂 吉西他滨 晚期肺鳞状细胞癌 一线化疗 不良反应 

分 类 号：R453[医药卫生—治疗学]